BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 33052237)

  • 1. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
    Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
    J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
    Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
    Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
    Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
    Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.
    Bidère N; Ngo VN; Lee J; Collins C; Zheng L; Wan F; Davis RE; Lenz G; Anderson DE; Arnoult D; Vazquez A; Sakai K; Zhang J; Meng Z; Veenstra TD; Staudt LM; Lenardo MJ
    Nature; 2009 Mar; 458(7234):92-6. PubMed ID: 19118383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assembly mechanism of the CARMA1-BCL10-MALT1-TRAF6 signalosome.
    David L; Li Y; Ma J; Garner E; Zhang X; Wu H
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1499-1504. PubMed ID: 29382759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
    Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
    Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.
    Xia M; David L; Teater M; Gutierrez J; Wang X; Meydan C; Lytle A; Slack GW; Scott DW; Morin RD; Onder O; Elenitoba-Johnson KSJ; Zamponi N; Cerchietti L; Lu T; Philippar U; Fontan L; Wu H; Melnick AM
    Cancer Discov; 2022 Aug; 12(8):1922-1941. PubMed ID: 35658124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
    Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist.
    Cheng J; Maurer LM; Kang H; Lucas PC; McAllister-Lucas LM
    Cell Immunol; 2020 Sep; 355():104158. PubMed ID: 32721634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular architecture and regulation of BCL10-MALT1 filaments.
    Schlauderer F; Seeholzer T; Desfosses A; Gehring T; Strauss M; Hopfner KP; Gutsche I; Krappmann D; Lammens K
    Nat Commun; 2018 Oct; 9(1):4041. PubMed ID: 30279415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
    Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.
    Staal J; Driege Y; Haegman M; Borghi A; Hulpiau P; Lievens L; Gul IS; Sundararaman S; Gonçalves A; Dhondt I; Pinzón JH; Braeckman BP; Technau U; Saeys Y; van Roy F; Beyaert R
    Front Immunol; 2018; 9():1136. PubMed ID: 29881386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.